Molecular Farming in Plants: The Long Road to the Market

  • Rainer Fischer
  • Johannes F. Buyel
  • Stefan Schillberg
  • Richard M. Twyman
Chapter
Part of the Biotechnology in Agriculture and Forestry book series (AGRICULTURE, volume 68)

Abstract

Recombinant proteins can be produced on a commercial scale using a diverse array of host systems based on microbes, animals, and plants. Commercially established processes have resolved to a small number of standard platforms, including the bacterium Escherichia coli, the yeasts Saccharomyces cerevisiae and Pichia pastoris, and certain well-characterized insect and mammalian cell lines. In contrast, many different plant-based systems have been developed and only in the last few years have standardized platforms begun to emerge. The diversity of plant-based platforms has been advantageous to molecular farming by helping to overcome technical issues, but the failure to focus on specific platforms has made the transition from experimental development to a viable commercial process a long and difficult one. As well as the technical and economic principles required to develop a viable manufacturing processes, plants have also been held back by the lack of a harmonized regulatory system for plant-derived pharmaceutical products, such that much of the early commercial development of molecular farming focused on non-pharmaceutical proteins. Despite these hurdles, pharmaceutical molecular farming is now firmly established in the market, and we are witnessing the dawn of a new age in which plants are regarded as competitive platforms for the commercial production of diverse recombinant pharmaceutical protein products.

Notes

Acknowledgments

We acknowledge funding from the EU projects Pharma-Planta (LSHB-CT-2003-503565) and CoMoFarm (227420), the COST Action Molecular Farming (FA0804), and the ERC advanced grant Future-Pharma (269110).

References

  1. Aviezer D, Almon-Brill E, Shaaltiel Y et al (2009a) Novel enzyme replacement therapy for Gaucher disease: ongoing Phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells. Mol Genet Metab 96:S13–S14CrossRefGoogle Scholar
  2. Aviezer D, Brill-Almon E, Shaaltiel Y et al (2009b) A plant-derived recombinant human glucocerebrosidase enzyme—a preclinical and phase I investigation. PLoS One 4:e4792PubMedCentralPubMedCrossRefGoogle Scholar
  3. Azzoni AR, Kusnadi AR, Miranda EA et al (2002) Recombinant aprotinin produced in transgenic corn seed: extraction and purification studies. Biotechnol Bioeng 80:268–276PubMedCrossRefGoogle Scholar
  4. Azzoni AR, Farinas CS, Miranda EA (2005) Transgenic corn seed for recombinant protein production: relevant aspects on the aqueous extraction of native components. J Sci Food Agric 85:609–614CrossRefGoogle Scholar
  5. Bevan MW, Flavell RB, Chilton MD (1983) A chimaeric antibiotic resistance gene as a selectable marker for plant cell transformation. Nature 304:184–187CrossRefGoogle Scholar
  6. Buyel JF, Fischer R (2012) Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs. Biotechnol Bioeng 109:2575–2588PubMedCrossRefGoogle Scholar
  7. Buyel JF, Fischer R (2014a) Flocculation increases the efficacy of depth filtration during the downstream processing of recombinant pharmaceutical proteins produced in tobacco. Plant Biotechnol J 12:240–252PubMedCrossRefGoogle Scholar
  8. Buyel JF, Fischer R (2014b) Scale-down models to optimize a filter train for the downstream purification of recombinant pharmaceutical proteins produced in tobacco leaves. Biotechnol J 9:415–425PubMedCrossRefGoogle Scholar
  9. Buyel JF, Kaever T, Buyel JJ et al (2013a) Predictive models for the accumulation of a fluorescent marker protein in tobacco leaves according to the promoter/5’UTR combination. Biotechnol Bioeng 110:471–482Google Scholar
  10. Buyel JF, Woo JA, Cramer SM et al (2013b) The use of quantitative structure–activity relationship models to develop optimized processes for the removal of tobacco host cell proteins during biopharmaceutical production. J Chromatogr A 1322:18–28Google Scholar
  11. Buyel JF, Gruchow HM, Boes A et al (2014) Rational design of a host cell protein heat precipitation step can simplify the subsequent purification of recombinant proteins from tobacco. Biotechnol Bioeng 88:162–170Google Scholar
  12. Cardi T, Lenzi P, Maliga P (2010) Chloroplasts as expression platforms for plant-produced vaccines. Expert Rev Vaccines 9:893–911PubMedCrossRefGoogle Scholar
  13. Castilho A, Strasser R, Stadlmann J et al (2010) In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem 285:15923–15930PubMedCentralPubMedCrossRefGoogle Scholar
  14. Cox KM, Sterling JD, Regan JT et al (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591–1597PubMedCrossRefGoogle Scholar
  15. D'Aoust MA, Couture MM, Charland N et al (2010) The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 8:607–619PubMedCrossRefGoogle Scholar
  16. D’Aoust MA, Lavoie PO, Couture MM et al (2008) Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 6:930–940PubMedCrossRefGoogle Scholar
  17. EMEA (2002) Committee for Proprietary Medicinal Products (CPMP). Points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants (EMEA/CPMP/BWP/764/02). EMA, London, UKGoogle Scholar
  18. EMEA (2009) Committee for Proprietary Medicinal Products (CPMP). Guideline on the quality of biological active substances produced by stable transgene expression in higher plants (EMEA/CHMP/BWP/48316/2006). EMA, London, UKGoogle Scholar
  19. FDA/USDA (2002) Draft guidance. Drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals. FDA, Rockville, MD. http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM055424.pdf
  20. Fischer R, Schillberg S, Hellwig S et al (2012) GMP issues for plant-derived recombinant proteins. Biotechnol Adv 30:434–439PubMedCrossRefGoogle Scholar
  21. Giritch A, Marillonnet S, Engler C et al (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 103:14701–14706PubMedCentralPubMedCrossRefGoogle Scholar
  22. Gomord V, Fitchette AC, Menu-Bouaouiche L et al (2010) Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol J 8:564–587PubMedCrossRefGoogle Scholar
  23. Hiatt AH, Caffertey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76–78PubMedCrossRefGoogle Scholar
  24. Hofbauer A, Stoger E (2013) Subcellular accumulation and modification of pharmaceutical proteins in different plant tissues. Curr Pharm Des 19:5495–5502PubMedCrossRefGoogle Scholar
  25. Hood EE (2002) From green plants to industrial enzymes. Enzyme Microb Technol 30:279–283CrossRefGoogle Scholar
  26. Hood EE, Witcher DR, Maddock S et al (1997) Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breed 3:291–306CrossRefGoogle Scholar
  27. Hood EE, Woodard SL, Horn ME (2002) Monoclonal antibody manufacturing in transgenic plants—myths and realities. Curr Opin Biotechnol 13:630–635PubMedCrossRefGoogle Scholar
  28. Huang Z, Phoolcharoen W, Lai H et al (2010) High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 106:9–17PubMedCentralPubMedGoogle Scholar
  29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2012) Q11. Development and manufacture of drug substances (chemical entities and biotechnological/biological entities). Fed Regist 77:69634–69635Google Scholar
  30. Kusnadi AR, Evangelista RL, Hood EE et al (1998) Processing of transgenic corn seed and its effect on the recovery of recombinant β-glucuronidase. Biotechnol Bioeng 60:44–52PubMedCrossRefGoogle Scholar
  31. Lamphear BJ, Streatfield SJ, Jilka JM et al (2002) Delivery of subunit vaccines in maize seed. J Control Release 85:169–180PubMedCrossRefGoogle Scholar
  32. Landry N, Ward BJ, Trepanier S et al (2010) Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5:e15559PubMedCentralPubMedCrossRefGoogle Scholar
  33. Ma JKC, Drake PMW, Christou P (2003) The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 4:794–805PubMedCrossRefGoogle Scholar
  34. Menkhaus TJ, Bai Y, Zhang CM et al (2004) Considerations for the recovery of recombinant proteins from plants. Biotechnol Prog 20:1001–1014PubMedCrossRefGoogle Scholar
  35. Nikolov ZL, Woodard SL (2004) Downstream processing of recombinant proteins from transgenic feedstock. Curr Opin Biotechnol 15:479–486PubMedCrossRefGoogle Scholar
  36. Ogawa M, Kumamaru T, Satoh H et al (1987) Purification of protein body-I of rice seed and its polypeptide composition. Plant Cell Physiol 28:1517–1527Google Scholar
  37. Pandey A, Singh N, Mittal SK (2010) Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin 6:178–188PubMedCrossRefGoogle Scholar
  38. Paul MJ, Teh AY, Twyman RM et al (2013) Target product selection—where can molecular pharming make the difference? Curr Pharm Des 19:5478–5485PubMedCrossRefGoogle Scholar
  39. Pogue GP, Vojdani F, Palmer KE et al (2010) Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 8:638–654PubMedCrossRefGoogle Scholar
  40. Rademacher T, Sack M, Arcalis E et al (2008) Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J 6:189–201PubMedCrossRefGoogle Scholar
  41. Ramessar K, Rademacher T, Sack M et al (2008) Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc Natl Acad Sci USA 105:3727–3732PubMedCentralPubMedCrossRefGoogle Scholar
  42. Ramessar K, Sabalza M, Miralpeix B et al (2010) Can microbicides turn the tide against HIV? Curr Pharm Des 16:468–485PubMedCrossRefGoogle Scholar
  43. Rappuoli R, Dormitzer PR (2012) Influenza: options to improve pandemic preparation. Science 336:1531–1533PubMedCrossRefGoogle Scholar
  44. Sainsbury F, Lomonossoff GP (2008) Extremely high-level and rapid protein production in plants without the use of viral replication. Plant Physiol 148:1212–1218PubMedCentralPubMedCrossRefGoogle Scholar
  45. Schillberg S, Raven N, Fischer R et al (2013) Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr Pharm Des 19:5531–5542PubMedCrossRefGoogle Scholar
  46. Shaaltiel Y, Bartfeld D, Hashmueli S et al (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 5:579–590PubMedCrossRefGoogle Scholar
  47. Shoji Y, Chichester JA, Bi H et al (2008) Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 26:2930–2934PubMedCrossRefGoogle Scholar
  48. Shoji Y, Chichester JA, Jones M et al (2011) Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 7:41–50PubMedCrossRefGoogle Scholar
  49. Soria-Guerra RE, Rosales-Mendoza S, Moreno-Fierros L et al (2011) Oral immunogenicity of tomato-derived sDPT polypeptide containing Corynebacterium diphtheriae, Bordetella pertussis and Clostridium tetani exotoxin epitopes. Plant Cell Rep 30:417–424PubMedCrossRefGoogle Scholar
  50. Spok A, Twyman RM, Fischer R et al (2008) Evolution of a regulatory framework for plant-made pharmaceuticals. Trends Biotechnol 26:506–517PubMedCrossRefGoogle Scholar
  51. Sriraman R, Bardor M, Sack M et al (2004) Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-α(1,3)-fucose residues. Plant Biotechnol J 2:279–287PubMedCrossRefGoogle Scholar
  52. Stoger E, Sack M, Nicholson L et al (2005) Recent progress in plantibody technology. Curr Pharm Des 11:2439–2457PubMedCrossRefGoogle Scholar
  53. Strasser R, Castilho A, Stadlmann J et al (2009) Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous β1,4-galactosylated N-glycan profile. J Biol Chem 284:20479–20485PubMedCentralPubMedCrossRefGoogle Scholar
  54. Streatfield SJ, Lane JR, Brooks CA et al (2003) Corn as a production system for human and animal vaccines. Vaccine 21:812–815PubMedCrossRefGoogle Scholar
  55. Tiwari S, Verma PC, Singh PK et al (2009) Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 27:449–467PubMedCrossRefGoogle Scholar
  56. Tremblay R, Wang D, Jevnikar AM et al (2010) Tobacco, a highly efficient green bioreactor for production of therapeutic proteins. Biotechnol Adv 28:214–221PubMedCrossRefGoogle Scholar
  57. Triguero A, Cabrera G, Cremata JA et al (2005) Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol J 3:449–457PubMedCrossRefGoogle Scholar
  58. Twyman RM, Stoger E, Schillberg S et al (2003) Molecular farming in plants: host systems and expression technology. Trends Biotechnol 21:570–578PubMedCrossRefGoogle Scholar
  59. Twyman RM, Schillberg S, Fischer R (2005) Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 10:185–218PubMedCrossRefGoogle Scholar
  60. Twyman RM, Schillberg S, Fischer R (2013) Optimizing the yield of recombinant pharmaceutical proteins in plants. Curr Pharm Des 19:5486–5494PubMedCrossRefGoogle Scholar
  61. Verma D, Moghimi B, LoDuca PA et al (2010) Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA 107:7101–7106PubMedCentralPubMedCrossRefGoogle Scholar
  62. Vézina LP, Faye L, Lerouge P et al (2009) Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotechnol J 7:442–455PubMedCrossRefGoogle Scholar
  63. Whaley KJ, Hiatt A, Zeitlin L (2011) Emerging antibody products and Nicotiana manufacturing. Hum Vaccin 7:349–356PubMedCentralPubMedCrossRefGoogle Scholar
  64. Wilken LR, Nikolov ZL (2006) Factors influencing recombinant human lysozyme extraction and cation exchange adsorption. Biotechnol Prog 22:745–752PubMedCrossRefGoogle Scholar
  65. Wilken LR, Nikolov ZL (2010) Evaluation of alternatives for human lysozyme purification from transgenic rice: impact of phytic acid and buffer. Biotechnol Prog 26:1303–1311PubMedCrossRefGoogle Scholar
  66. Wilken LR, Nikolov ZL (2012) Recovery and purification of plant-made recombinant proteins. Biotechnol Adv 30:419–433PubMedCrossRefGoogle Scholar
  67. Witcher D, Hood EE, Peterson D et al (1998) Commercial production of β-glucuronidase (GUS): a model system for the production of proteins in plants. Mol Breed 4:301–312CrossRefGoogle Scholar
  68. Xu J, Ge X, Dolan MC (2011) Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol Adv 29:278–299PubMedCrossRefGoogle Scholar
  69. Yusibov V, Streatfield SJ, Kushnir N (2011) Clinical development of plant-produced recombinant pharmaceuticals. Vaccines, antibodies and beyond. Hum Vaccin 7:313–321PubMedCrossRefGoogle Scholar
  70. Zhong Q, Xu L, Zhang C et al (2007) Purification of recombinant aprotinin from transgenic corn germ fraction using ion exchange and hydrophobic interaction chromatography. Appl Microbiol Biotechnol 76:607–613PubMedCrossRefGoogle Scholar
  71. Zimmermann J, Saalbach I, Jahn D et al (2009) Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens. BMC Biotechnol 9:79PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Rainer Fischer
    • 1
    • 2
  • Johannes F. Buyel
    • 2
  • Stefan Schillberg
    • 1
  • Richard M. Twyman
    • 3
  1. 1.Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)AachenGermany
  2. 2.Institute for Molecular BiotechnologyRWTH Aachen UniversityAachenGermany
  3. 3.TRM LtdYorkUK

Personalised recommendations